Cherry SE Q2 2025 slides highlight e-health growth amid broader revenue decline

Cherry SE (ETR:C3RY) reported a challenging H1 2025 with revenue down 25% year-over-year to €46.0 million and an adjusted EBITDA margin of -5.0%, reflecting broad struggles across most segments and a difficult German economic climate. However, its Digital Health & Solutions (DH&S) division showed strong profitability, driven by a 500% surge in regulatory-mandated e-health terminal applications. The company is actively restructuring, having cut inventory by 48% and secured financing adjustments, including a loan extension and the sale of its Hygiene Peripherals business for €21 million, while forecasting an improved full-year 2025 adjusted EBITDA margin of 0-2%.

Analysis

Cherry SE (C3RY) is undergoing a significant strategic and operational overhaul amidst a severe downturn in its legacy businesses. H1 2025 results reveal a stark dichotomy: a 25% year-over-year revenue decline to €46.0 million and a negative 5.0% adjusted EBITDA margin, driven by weakness in the Components and Gaming/Office Peripherals segments which are battling a recessionary German economy and market normalization. In stark contrast, the Digital Health & Solutions (DH&S) division stands out as a high-growth, profitable engine, posting €9.9 million in H1 adjusted EBITDA. This strength is fueled by regulatory mandates in Germany, evidenced by a 500% YoY surge in SMC-B card applications and a large untapped market of 32,000 elderly care institutions. Management is actively restructuring, having successfully cut inventory by 48% from its peak, divested the Hygiene Peripherals unit for €21 million, and secured financing through 2027. The company's pivot towards a recurring software revenue model, centered on DH&S and the new TI-Messenger platform, is a clear strategic shift. The appointment of a new, experienced CFO adds credibility to this turnaround effort, though the optimistic full-year guidance for a 0-2% adjusted EBITDA margin implies a challenging but necessary H2 recovery.

Key Decisions for Investors

• Consider Cherry SE as a high-risk, high-reward turnaround investment, where the core thesis is whether the profitable, high-growth Digital Health & Solutions (DH&S) segment can successfully scale to offset the significant revenue declines in the legacy hardware businesses.
• Track management's execution against its FY2025 guidance for an adjusted EBITDA margin of 0-2%; achieving this target would signal that inventory reduction, cost controls, and the H2 recovery are materializing as projected.
• Pay close attention to catalysts in the DH&S segment, specifically the regulatory-driven growth in e-health terminal deployments and the upcoming TI-Messenger certification, as these are crucial for the company's strategic pivot to a more predictable, software-centric revenue model.